Lineage Cell Company Insiders
| LCTX Stock | USD 0.57 0.04 6.56% |
Lineage Cell employs about 68 people. The company is managed by 11 executives with a total tenure of roughly 159 years, averaging almost 14.0 years of service per executive, having 6.18 employees per reported executive. Break down of Lineage Cell's management performance can provide insight into the company performance.
Lineage |
Lineage Cell Management Team Effectiveness
The company has return on total asset (ROA) of (0.1286) % which means that it has lost $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3504) %, meaning that it created substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.31 in 2024. At this time, Lineage Cell's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 65.7 M in 2024, whereas Total Current Assets are likely to drop slightly above 21.1 M in 2024.Common Stock Shares Outstanding is likely to rise to about 181.3 M in 2024, whereas Net Loss is likely to drop (31.7 M) in 2024.
Lineage Cell Workforce Comparison
Lineage Cell Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,901. Lineage Cell holds roughly 68.0 in number of employees claiming about 2.34% of equities under Health Care industry.
Lineage Cell Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lineage Cell insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lineage Cell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Lineage Cell insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Samuel George A. Iii few days ago Acquisition by Samuel George A. Iii of 15000 shares of Lineage Cell at 0.6 subject to Rule 16b-3 | ||
Mulroy Michael H. over a week ago Acquisition by Mulroy Michael H. of 40000 shares of Lineage Cell at 0.566 subject to Rule 16b-3 | ||
Hogge Gary S. over two months ago Disposition of 5310 shares by Hogge Gary S. of Lineage Cell at 1.35 subject to Rule 16b-3 | ||
Jill Howe over three months ago Acquisition by Jill Howe of 10500 shares of Lineage Cell at 0.89 subject to Rule 16b-3 | ||
Bradsher Neal C over three months ago Acquisition by Bradsher Neal C of 75000 shares of Lineage Cell at 0.9541 subject to Rule 16b-3 | ||
Culley Brian M over six months ago Acquisition by Culley Brian M of 10000 shares of Lineage Cell at 1.05 subject to Rule 16b-3 | ||
Jill Howe over six months ago Acquisition by Jill Howe of 650000 shares of Lineage Cell at 1.13 subject to Rule 16b-3 | ||
West Michael D over a year ago Payment of 587 shares by West Michael D of Lineage Cell subject to Rule 16b-3 |
Lineage Cell Notable Stakeholders
A Lineage Cell stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Lineage Cell often face trade-offs trying to please all of them. Lineage Cell's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Lineage Cell's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MBA MA | President CEO | Profile | |
| William MBA | President Corporation | Profile | |
| Charlotte Hubbert | Vice Development | Profile | |
| Jill Howe | CFO Officer | Profile | |
| DVM Dvm | VP Affairs | Profile | |
| Alexandra Hernandez | Senior Controller | Profile | |
| JD III | General Secretary | Profile | |
| Ioana Hone | Director Relations | Profile | |
| William Annett | Pres Corp | Profile | |
| Rami Skaliter | Chief Neurosciences | Profile | |
| Harold Waitz | Vice Control | Profile |
About Lineage Cell Management Performance
The success or failure of an entity such as Lineage Cell Therapeutics often depends on how effective the management is. Lineage Cell management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Lineage management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Lineage management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.52) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.34) | (0.32) |
Please note, the imprecision that can be found in Lineage Cell's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lineage Cell Therapeutics. Check Lineage Cell's Beneish M Score to see the likelihood of Lineage Cell's management manipulating its earnings.
Lineage Cell Workforce Analysis
Traditionally, organizations such as Lineage Cell use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Lineage Cell within its industry.Lineage Cell Manpower Efficiency
Return on Lineage Cell Manpower
| Revenue Per Employee | 131.5K | |
| Revenue Per Executive | 813.2K | |
| Net Loss Per Employee | 316K | |
| Net Loss Per Executive | 2M | |
| Working Capital Per Employee | 301.2K | |
| Working Capital Per Executive | 1.9M |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.